Abemaciclib (Verzenio)
Other Medications · Approved since 2017
Description
Abemaciclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor that blocks cell cycle progression in cancer cells. In colorectal cancer, abemaciclib is being evaluated in combination with standard chemotherapy agents like 5-fluorouracil and targeted therapies including cetuximab and ERK inhibitors. The drug shows particular interest in tumors harboring KRAS mutations, which are present in approximately 40-50% of colorectal cancers and historically difficult to target effectively.
Mechanism of Action
Abemaciclib specifically inhibits cyclin-dependent kinases 4 and 6, which are essential regulators of the G1/S cell cycle checkpoint. By blocking CDK4/6 activity, the drug prevents phosphorylation of the retinoblastoma protein, leading to cell cycle arrest in the G1 phase and reduced cancer cell proliferation.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Verzenio |
| Category | Other Medications |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | Oral |
| Year Approved | 2017 |
| Clinical Trials | 11 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.